Associate Professor Aaron Sverdlov

Associate Professor Aaron Sverdlov

Director of Heart Failure

School of Medicine and Public Health

Career Summary

Biography

Associate Professor Aaron Sverdlov is a cardiologist and clinician-scientist with proven track record in basic through to clinical research. His research interests encompass a broad spectrum of topics related to heart failure.

Personal statement

I am committed to improving management and outcomes for patients with heart failure through better understanding of mechanisms involved and discovering novel biomarkers and therapies.

Biography

Dr Sverdlov received his medical degree (MBBS) from the University of Adelaide, Australia in 2000. Then he completed his post-graduate training in general medicine and cardiology, including serving as a Chief Medical Resident for 2 years. He was admitted to the Fellowship of the Royal Australasian College of Physicians (FRACP) in December 2007, and then appointed staff specialist in cardiology at the Queen Elizabeth Hospital and Lyell McEwin Hospital from February 2008.

Aaron Sverdlov was awarded his PhD in 2012 from University of Adelaide. His doctoral work was on pathogenesis of aortic valve disease: Aaron led the aortic valve stenosis group at the Queen Elizabeth Hospital and provided the first evidence in humans that progression of aortic stenosis is amenable to treatment with renin-angiotensin-aldosterone system inhibitors. He was then awarded an NHMRC CJ Martin and RACP Fellowships to undertake postdoctoral work with Prof WS Colucci at Boston University (2012-15). There he studied mechanisms regulating cardiac function and energetics in models of metabolic heart disease/diastolic dysfunction utilizing state-of-the-art techniques and methodologies. He proved that mitochondrial ROS play a key pathogenic role in metabolic heart disease and identified reactive cysteines (never previously described) in mitochondrial complex II that modulate its function and lead to cardiac energetic impairment. He was also involved in describing a new method for quantitation of FDG PET/CT in cardiac sarcoidosis: this work has been heavily cited and this method has been adopted by a number of institutions. Aaron's postdoctoral work gained him a reputation as an expert and leader in mitochondrial redox field: he was awarded AHA Postdoctoral Fellowship. 

Upon return to Australia in 2015, in partnership with his wife, A/Prof Doan Ngo, he established and co-led Cardiometabolic research group at the Basil Hetzel Institute in Adelaide. In 2 years they have attracted over $720,000 in research funding across a variety of cardiovascular areas, including obesity and angiogenesis, weight loss and exercise physiology, novel biomarkers and cardio-oncology.

Aaron relocated to Newcastle in 2017 where he was appointed as an Associate Professor and Director of Heart Failure at the University of Newcastle. He has a Clinical Academic appointment as a cardiologist at the John Hunter Hospital and is a Clinical Lead of Heart Failure Services for Hunter New England Local Health District.

Aaron has just been awarded 4-year Heart Foundation Future Leader Fellowship for his research program "Bench-to-bedside approach to improving management and outcomes for patients with heart failure".

Research Expertise

Aaron Sverdlov's research encompasses a full spectrum of translation from bench to bedside and service delivery.  He has a basic and translational lab at the Hunter Medical Research Institute and shares a research lab with A/Prof Doan Ngo on the Callaghan Campus. His clinical research is at the John Hunter Hospital and other sites across the Health District. 

Broad goals of Aaron's research program are to improve care and health outcomes for patients with heart disease through better understanding of mechanisms responsible for development of heart failure, prevention and early detection of heart disease through development of novel biomarkers and improved delivery of healthcare by dedicated and integrated multidisciplinary approach.

Aaron's specific research interests directions are:

- mechanisms underlying development of heart failure, especially heart failure due to obesity and diabetes

- role of mitochondria and redox stress in heart failure

- mechanisms of development of chemotherapy-mediated cardiotoxicity

- role of novel biomarkers in early detection of various forms of heart disease

- basic and clinical factors reponsible for development and progression of aortic valve disease

- development and evaluation of integrated multidisciplinary heart failure service incorporating research and innovation

- development and evaluation of cardio-oncology clinical and translational program

- evaluation of new treatment options for patients with obesity, heart failure and chemotherapy-induced cardiotoxicity

Across these projects Aaron has a number of local, national and international collaborators.

Track record, peer review and service to the field

Aaron has 44 career (since 2008) peer-reviewed publications and 4 book chapters (including chapters on Oxidative Stress in Heart Failure in the textbook “Heart Failure: A Companion to Braunwald’s Heart Disease”) with over 750 citations in last 5 years and has had 74 presentations at international and national meetings. He received over 20 competitive grants, with 17 in the last 5 years (total >$2M AUD).

Aaron Sverdlov serves on the NHMRC ECF Biomedical Panel (2015-6), NHMRC Cardiovascular Diseases GRP (2016-7), Heart Foundation of Australia Postdoctoral Fellowships Committee (2017), Hunter New England Local Health District TRGS EOI review panel (2017), American Heart Association Cardiac Biology Program Peer Review Committee (2017-8) and Rebecca Cooper Medical Research Foundation grant advisory panel (2016). 

He is also a reviewer for the European Society of Cardiology (ESC), Australian Research Council (ARC), Cardiac Society of Australia and New Zealand (CSANZ), Diabetes Australia and Society for Redox Biology and Medicine (SFRBM). 

Aaron is an Associate Editor for 2 international journals (Heart Lung and Circulation and Egyptian Heart Journal) ans is on editorial board of Reactive Oxygen Species. He is a regular reviewer for multiple leading cardiovascular, pharmacology and basic science journals including Circulation Research, JACC, Hypertension, JMCC, International Journal of Cardiology, Antioxidant Redox Signaling, Cardiovascular Therapeutics and British Journal of Pharmacology.

Teaching and Education

Aaron has been involved in undergraduate teaching in medicine at the University of Newcastle and University of Adelaide as well as Boston University, USA. He supervised numerous clinical students and physician trainees especially in his capacity as the Chief Medical Resident. As a postdoctoral fellow at the Boston University he supervised and mentored honours, PhD and MD/PhD students. Currently he co-supervises 4 PhD, 1 honours students  and 2 postdoctoral fellows across University of Newcastle, University of Adelaide and Flinders University of SA. He is involved in porefessional education of general practitioners and physicians in community and hospital settings.

Collaborations

In addition to multiple collaborations within University of Newcastle, HMRI and Hunter New England Local Health District, Aaron has active research collaborations with University of Adelaide, Flinders University of SA, University of Sydney, Boston University (USA) and University of East Anglia (UK).


Qualifications

  • Doctor of Philosophy, University of Adelaide
  • Bachelor of Medicine, Bachelor of Surgery, University of Adelaide

Keywords

  • Aortic valve stenosis
  • Biomarkers
  • Cardio-oncology
  • Cardiomyopathy
  • Clinical cardiology
  • Heart Failure
  • Mitochondria
  • Obesity and heart disease
  • Oxidative stress

Languages

  • English (Fluent)
  • Russian (Fluent)

Fields of Research

Code Description Percentage
110107 Metabolic Medicine 10
110201 Cardiology (incl. Cardiovascular Diseases) 80
111299 Oncology and Carcinogenesis not elsewhere classified 10

Professional Experience

UON Appointment

Title Organisation / Department
Director of Heart Failure University of Newcastle
School of Medicine and Public Health
Australia

Academic appointment

Dates Title Organisation / Department
7/12/2017 -  Fellow - Heart Failure Association (FHFA) of the ESC Heart Failure Association of the European Society of Cardiology
France
1/11/2015 -  Fellow - American College of Cardiology (FACC) American College of Cardiology
United States
1/07/2014 - 15/04/2015 AHA Postdoctoral Fellow Boston University MA
Cardiovascular Medicine
United States
1/01/2013 -  Fellow - European Society of Cardiology (FESC) European Society of Cardiology
France
1/07/2012 - 22/05/2017 NHMRC CJ Martin Fellow University of Adelaide
Australia
1/07/2012 - 15/04/2015 NHMRC CJ Martin Fellow Boston University MA
Cardiovascular Medicine
United States
1/10/2011 -  Fellow - Cardiac Society of Australia and New Zealand (FCSANZ) Cardiac Society of Australia and NewZealand
Australia
17/12/2007 -  Fellow - Royal Australasian College of Physicians (FRACP) The Royal Australasian College of Physicians
Australia

Professional appointment

Dates Title Organisation / Department
1/07/2017 -  Clinical Lead - Heart Failure Service Hunter New England Local Health District NSW Health
Cardiovascular Medicine
Australia
1/05/2017 -  Clinical Academic Cardiologist John Hunter Hospital
Cardiovascular Medicine
Australia
1/07/2012 - 22/05/2017 Senior Staff Specialist - Cardiology Queen Elizabeth Hospital
Cardiology Department
Australia
1/02/2008 - 30/06/2012 Staff Specialist - Cardiology Queen Elizabeth Hospital
Cardiology Department
Australia

Teaching appointment

Dates Title Organisation / Department
1/01/2005 - 31/12/2006 Chief Medical Resident Queen Elizabeth Hospital
Department of Medicine
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Book (1 outputs)

Year Citation Altmetrics Link
2010 Chirkov YY, Sverdlov AL, Horowitz JD, Beneficial effects of perhexiline in cardiovascular disease states (2010)

© 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the... [more]

© 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline¿s reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease.


Chapter (1 outputs)

Year Citation Altmetrics Link
2016 Sawyer DB, Sverdlov AL, Colucci WS, 'Oxidative Stress in Heart Failure', Heart Failure A Companion to Braunwald's Heart Disease, Elsevier, Philadelphia 127-139 (2016)

Journal article (44 outputs)

Year Citation Altmetrics Link
2017 Sverdlov AL, Ngo DTM, 'Response to the letter to editor: Galectin-3 and atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 229 2-2 (2017)
DOI 10.1016/j.ijcard.2016.12.006
2017 Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults.', PLoS One, 12 e0174435 (2017)
DOI 10.1371/journal.pone.0174435
2016 Miller EJ, Calamaras T, Elezaby A, Sverdlov A, Qin F, Luptak I, et al., 'Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)
DOI 10.1161/JAHA.115.002277
2016 Sverdlov AL, Figtree GA, Horowitz JD, Ngo DTM, 'Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome', MEDIATORS OF INFLAMMATION, (2016)
DOI 10.1155/2016/8254590
2016 Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, et al., 'Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)
DOI 10.1161/JAHA.115.002555
Citations Scopus - 11Web of Science - 11
2016 Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al., 'New onset atrial fibrillation is associated with elevated galectin-3 levels', International Journal of Cardiology, 223 48-49 (2016) [C1]
DOI 10.1016/j.ijcard.2016.08.172
Citations Scopus - 4Web of Science - 4
2016 Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]
DOI 10.1016/j.diabet.2016.05.002
Citations Scopus - 1Web of Science - 1
2015 Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]
DOI 10.1016/j.yjmcc.2014.07.018
Citations Scopus - 22Web of Science - 19
2015 Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015)
DOI 10.1016/j.yjmcc2014.12.001
Citations Web of Science - 13
2015 Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]
DOI 10.1371/journal.pone.0144025
Citations Scopus - 8Web of Science - 9
2015 Taniguchi Y, Takahashi Y, Toba T, Yamada S, Yokoi K, Kobayashi S, et al., 'Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area', European Heart Journal - Cardiovascular Imaging, 16 i11-i28 (2015)
DOI 10.1093/ehjci/jev051
2015 Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)
DOI 10.3978/j.issn.2072-1439.2015.12.40
Citations Scopus - 1Web of Science - 1
2015 Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]
DOI 10.1016/j.yjmcc2014.12.001
Citations Scopus - 15Web of Science - 14
2014 Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)
DOI 10.1055/s-0034-1389082
Citations Scopus - 4Web of Science - 4
2014 Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)
DOI 10.1007/s10557-014-6538-5
Citations Scopus - 20Web of Science - 22
2014 Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)
DOI 10.1007/s12350-014-9901-9
Citations Scopus - 32Web of Science - 33
2014 Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)
DOI 10.1161/JAHA.114.000973
Citations Scopus - 10Web of Science - 7
2013 Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]
DOI 10.1016/j.amjmed.2012.12.015
Citations Scopus - 7
2013 Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013)
DOI 10.1111/bph.12152
Citations Scopus - 12Web of Science - 11
2013 Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)
DOI 10.1016/j.ijcard.2013.07.159
Citations Scopus - 15Web of Science - 17
2013 Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)
DOI 10.1161/HYPERTENSIONAHA.112.196253
Citations Scopus - 5Web of Science - 4
2013 Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)
DOI 10.1007/s10557-013-6481-x
Citations Scopus - 8Web of Science - 5
2013 Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)
DOI 10.1016/j.niox.2013.08.006
Citations Scopus - 11Web of Science - 8
2012 Neil C, Thanh HN, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al., 'Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI', HEART, 98 1278-1284 (2012)
DOI 10.1136/heartjnl-2011-301481
Citations Scopus - 32Web of Science - 30
2012 Ngo DT, Sverdlov AL, Horowitz JD, 'Prevention of aortic valve stenosis: A realistic therapeutic target?', PHARMACOLOGY & THERAPEUTICS, 135 78-93 (2012)
DOI 10.1016/j.pharmthera.2012.04.001
Citations Scopus - 16Web of Science - 13
2012 Sverdlov AL, Ngo DT, Horowitz JD, 'Redefining the natural history of calcific aortic stenosis: lessons from Laennec', JOURNAL OF INTERNAL MEDICINE, 271 569-572 (2012)
DOI 10.1111/j.1365-2796.2012.02520.x
2012 Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD, 'Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics', European Heart Journal, 33 2419-2425 (2012) [C1]
DOI 10.1093/eurheartj/ehs171
Citations Scopus - 17Web of Science - 15
2012 Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong C-R, Stansborough J, et al., 'Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history', EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 10 215-221 (2012)
Citations Scopus - 16Web of Science - 10
2012 Sverdlov AL, Ngo DTM, Horowitz JD, 'Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2 43-49 (2012)
Citations Web of Science - 3
2011 Ngo DTM, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Mechanistic considerations', British Journal of Pharmacology, 162 722-732 (2011) [C1]
DOI 10.1111/j.1476-5381.2010.01084.x
Citations Scopus - 19Web of Science - 21
2011 Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD, 'Pathogenesis of aortic stenosis: not just a matter of wear and tear.', Am J Cardiovasc Dis, 1 185-199 (2011)
Citations Web of Science - 11
2011 Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, et al., 'N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy', AMERICAN JOURNAL OF CARDIOLOGY, 108 1316-1321 (2011)
DOI 10.1016/j.amjcard.2011.06.047
Citations Scopus - 51Web of Science - 44
2011 Ling L-H, Chik W, Averbuj P, Pati PK, Sverdlov AL, Ngo DTM, et al., 'Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline', THERAPEUTIC DRUG MONITORING, 33 251-256 (2011)
DOI 10.1097/FTD.0b013e31820dd8e9
Citations Scopus - 4Web of Science - 4
2011 Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD, 'Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects', INTERNATIONAL JOURNAL OF CARDIOLOGY, 150 33-38 (2011)
DOI 10.1016/j.ijcard.2010.02.024
Citations Scopus - 8Web of Science - 6
2011 Sverdlov AL, Ngo DTM, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, et al., 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 41-46 (2011)
DOI 10.1016/j.niox.2011.04.009
Citations Scopus - 7Web of Science - 7
2011 Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 326-330 (2011)
DOI 10.1016/j.niox.2011.06.005
Citations Scopus - 26Web of Science - 22
2010 Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL, 'Modulation of myocardial metabolism: An emerging therapeutic principle', Current Opinion in Cardiology, 25 329-334 (2010)
DOI 10.1097/HCO.0b013e328339f191
Citations Scopus - 27Web of Science - 27
2010 Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD, 'Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?', AMERICAN JOURNAL OF MEDICINE, 123 335-341 (2010)
DOI 10.1016/j.amjmed.2009.09.024
Citations Scopus - 61Web of Science - 57
2010 Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD, 'Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure', CARDIOVASCULAR DRUGS AND THERAPY, 24 131-137 (2010)
DOI 10.1007/s10557-010-6233-0
Citations Scopus - 7Web of Science - 6
2009 Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD, 'Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine', PHARMACOLOGICAL RESEARCH, 60 503-507 (2009)
DOI 10.1016/j.phrs.2009.06.006
Citations Scopus - 11Web of Science - 6
2009 Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD, 'Determinants of Occurrence of Aortic Sclerosis in an Aging Population', JACC-CARDIOVASCULAR IMAGING, 2 919-927 (2009)
DOI 10.1016/j.jcmg.2009.03.016
Citations Scopus - 35Web of Science - 33
2008 Sverdlov AL, Taylor K, Elkington AG, Zeitz CJ, Beltrame JF, 'Cardiac magnetic resonance imaging identifies the elusive perivalvular abscess', CIRCULATION, 118 E1-E3 (2008)
DOI 10.1161/CIRCULATIONAHA.107.727339
Citations Scopus - 2Web of Science - 2
2008 Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, et al., 'Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein', EUROPEAN JOURNAL OF PHARMACOLOGY, 590 290-296 (2008)
DOI 10.1016/j.ejphar.2008.05.051
Citations Scopus - 20Web of Science - 26
2008 Chan WPA, Sverdlov AL, Horowitz JD, 'Management of the metabolic syndrome in cardiovascular disease', Current Treatment Options in Cardiovascular Medicine, 10 27-38 (2008)

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, ... [more]

The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states. The clustering of these metabolic risk factors significantly increases the risk of type 2 diabetes and promotes vascular endothelial dysfunction, inflammation, and increased oxidative stress. The net result is an increase in the risk of atherosclerotic cardiovascular disease. Therefore, management of MS is of utmost importance, especially considering its rapidly increasing prevalence in a population with rising obesity rates and its significant cardiovascular implications. The primary management of this syndrome involves the correction of the underlying risk factors - obesity, physical inactivity, and an atherogenic diet - with lifestyle modifications including increased physical activity and dietary modification. Smoking cessation also should be encouraged. However, pharmacologic therapies are often required to address cardiovascular risk factors. These agents can be categorized broadly into 1) anorectic agents, 2) insulin-sensitizing agents, 3) statins, and 4) renin-angiotensin system antagonists. Emerging therapies include adipokines, endocannabinoid inhibitors, and metabolic modulators, such as perhexiline and trimetazidine. To date, these therapies have not been shown to normalize the metabolic and cardiovascular burden of MS, and there still is no single therapeutic agent for its management. Copyright © 2008 by Current Medicine Group LLC.

DOI 10.1007/s11936-008-0004-2
Citations Scopus - 1
Show 41 more journal articles

Conference (32 outputs)

Year Citation Altmetrics Link
2016 Chua SJ, Ajaero C, Assadi-Khansari B, McGavigan A, Horowitz JD, Sverdlov AL, Ngo DTM, 'Galectin 3 is markedly elevated in severe heart failure and predicts improvement in LV volumes post cardiac resynchronisation therapy', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)
2016 Assadi-Khansari B, Chua SJ, Chapman M, Ali O, Nguyen H, Horowitz JD, et al., 'Follistatin-like 3 predicts aortic root enlargement in patients with bicuspid aortic valve', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)
2016 Chua SJ, Ajaero C, Assadi-Khansari B, Mcgavigan A, Horowitz JD, Ngo DT, Sverdlov AL, 'Galectin 3 predicts improvement in LV volumes after Cardiac Resynchronisation Therapy', EUROPEAN JOURNAL OF HEART FAILURE (2016)
2016 Liu S, Assadi-Khansari B, Ajaero C, Chua SJ, Horowitz JD, Ngo DT, Sverdlov AL, 'Follistatin-Like 3 is Elevated In Acute Heart Failure Patients', CIRCULATION, Pentagon City, VA (2016)
2014 Sverdlov AL, Elezaby A, Qin F, Behring JB, Bachschmid MM, Luptak I, et al., 'Oxidative Protein Modifications Mediate Mitochondrial Dysfunction in Metabolic Heart Disease: Correction ex vivo and in vivo', CIRCULATION (2014)
2014 Luptak I, Sverdlov AL, Elezaby A, Miller EJ, Pimentel DR, Liesa M, et al., 'Western Diet for One Month Impairs Myocardial Energetics and Both Systolic and Diastolic Pump Function in the Mouse Heart', CIRCULATION (2014)
2014 Elezaby A, Sverdlov AL, Tu VH, Qin F, Rimer J, Schaffer JE, et al., 'Metabolic Remodeling in Mice with Cardiomyocyte-Specific Fatty Acid Overload', CIRCULATION (2014)
2013 Elezaby A, Sverdlov A, Tu V, Soni K, Liesa M, Liesa M, et al., 'Impairment of the PPARa/PGC1a Axis Compromises Mitochondrial Biogenesis and Function in Hearts With Cardiomyocyte-Specific Fatty Acid Transport Protein 1 (FATP1) Overexpression', CIRCULATION, Dallas, TX (2013)
2013 Amarasekera AT, Sverdlov AL, Roberts MS, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status', EUROPEAN HEART JOURNAL, Amsterdam, NETHERLANDS (2013)
2012 Chan WP, Ngo DT, Sverdlov A, Chirkov YY, Horowitz JD, 'Effects of Ageing on Nitric Oxide Signalling in Women: Comparison with Polycystic Ovarian Syndrome', CIRCULATION (2012)
2012 Nguyen TH, Neil A, Sverdlov A, Ngo D, Chan W, Chirkov Y, et al., 'Paradoxical preservation of NO signalling in Takotsubo cardiomyopathy', EUROPEAN HEART JOURNAL, Munchen, GERMANY (2012)
2012 Dautov RF, Chirkov YY, Ngo DT, Sverdlov AL, Kemp-Harper BK, Ritchie RH, Horowitz JD, 'The Nitric Oxide Redox Sibling Nitroxyl Partially Circumvents Platelet Nitric Oxide Resistance in Patients With Ischaemic Heart Disease', CIRCULATION (2012)
2011 Sverdlov AL, Ngo DT, Chan WP, Chapman MJ, Chirkov YY, Gersh BJ, et al., 'Progression of Early Aortic Valve Disease: Are ACE Inhibitors Protective?', CIRCULATION (2011)
2011 Chan WPA, Sverdlov AL, Ngo DT, Rajendran S, Chirkov YY, Horowitz JD, 'Impact of ageing on the platelet and vascular responses in women with polycystic ovary syndrome', EUROPEAN HEART JOURNAL (2011)
2011 Chan WPA, Sverdlov AL, Ngo DT, Chirkov YY, Horowitz JD, 'Does oral contraceptive therapy induce platelet nitric oxide resistance?', EUROPEAN HEART JOURNAL (2011)
2011 Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', EUROPEAN HEART JOURNAL (2011)
2011 Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', EUROPEAN HEART JOURNAL (2011)
2011 Ngo DTM, Chan WPA, Sverdlov AL, Horowitz JD, 'Determinants and cardiovascular correlates of vitamin D deficiency in australian women', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
2011 Sverdlov AL, Ngo DTM, Chirkov YY, Horowitz JD, 'Insights into the initiation of aortic stenosis: roles of ACE-inhibitors and vitamin D', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
2010 Neil CJ, Nguyen TH, Collings S, Mahadavan D, Kucia AM, Sverdlov A, et al., 'Tako-Tsubo Cardiomyopathy: a Slowly Resolving Pancarditis', CIRCULATION (2010)
2010 Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Ritchie RH, Marwick TH, et al., 'Relationship between LV mass and diastolic function is independent of NO generation', EUROPEAN HEART JOURNAL, Stockholm, SWEDEN (2010)
2010 Chan WP, Ngo DT, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Implications of insulin sensitivity on inflammatory activation and atherogenic risk in normal and PCOS females', EUROPEAN HEART JOURNAL, Stockholm, SWEDEN (2010)
2009 Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Heresztyn T, Horowitz JD, 'Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) Predict LV Mass Independent of Afterload', CIRCULATION, Orlando, FL (2009)
2009 Ngo DTM, Sverdlov AL, Mcneil JJ, Horowitz JD, 'Low 25-hydroxyvitamin D levels are associated with elevated plasma ADMA and C-reactive protein concentrations: nexus with cardiovascular disease', EUROPEAN HEART JOURNAL (2009)
2008 Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Horowitz JD, 'Is there a pharmacological hydralazine/nitrate interaction in chronic heart failure?', EUROPEAN HEART JOURNAL (2008)
Citations Web of Science - 1
2007 Ngo DT, Stafford I, Wuttke RD, Weedon H, Smith MD, Kelly DJ, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Role of thioredoxin interacting protein', CIRCULATION, Orlando, FL (2007)
2007 Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, Mcneil JJ, Horowitz JD, 'Aortic valve sclerosis is associated with impaired platelet responsiveness to nitric oxide', EUROPEAN HEART JOURNAL (2007)
2007 Ngo DTM, Stafford I, Wuttke RD, Weedon H, Smith MD, Sverdlov AL, et al., 'Ramipril retards progression of aortic valve stenosis: association with preservation of nitric oxide effects', EUROPEAN HEART JOURNAL (2007)
2006 Nightingale AK, Rajendran S, Sverdlov A, Mishra K, Ngo D, Heresztyn T, Horowitz JD, 'Aortic sclerosis precedes development of systemic endothelial dysfunction', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)
2006 Ngo DT, Wuttke RD, Stafford I, Rosenkranz AR, Sverdlov AL, Chirkov YY, et al., 'Effects of vitamin D2 supplementation on aortic valvular and vascular endothelial functions in a rabbit model of aortic stenosis', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)
2006 Chirkov YY, Rajendran S, Sverdlov AL, Horowitz JD, 'Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1-7) is mediated by its specific receptor and is associated with the suppression of superoxide release', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)
2006 Ngo DT, Wuttke RD, Weedon H, Nightingale AK, Sverdlov AL, Kennedy JA, Horowitz JD, 'Vitamin D2 supplementation induces aortic stenosis in rabbits', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)
Show 29 more conferences
Edit

Grants and Funding

Summary

Number of grants 24
Total funding $2,169,550

Click on a grant title below to expand the full details for that specific grant.


20177 grants / $737,000

Bench-to-bedside approach to improving management and outcomes for patients with heart failure$520,000

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Project Team Associate Professor Aaron Sverdlov
Scheme Future Leader Fellowship
Role Lead
Funding Start 2017
Funding Finish 2020
GNo G1700785
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Cardiometabolic research program$100,000

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Project Team Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz, AM
Scheme Vanguard Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701324
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Equipment Grant - Vevo 1100 Imaging System$20,000

Woodend Foundation Funding for Surgical and Clinical Research Equipment

Funding body: Faculty of Health and Medicine, University of Newcastle

Funding body Faculty of Health and Medicine, University of Newcastle
Scheme Faculty Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

Assessing the feasibility of angiotensin receptor blocker/neprilysin inhibitor (ARNI) in reducing the progression of aortic valve stenosis$10,000

Funding body: Universtiy of Newcastle

Funding body Universtiy of Newcastle
Scheme Linkage Pilot Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

EMCR EQUIPMENT GRANT$10,000

Funding body: Hunter Medical Research Institute (HMRI)

Funding body Hunter Medical Research Institute (HMRI)
Scheme Unknown
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

Dissecting hypertrophic pathways in obesity-mediated heart failure$2,000

Funding body: Faculty of Health and Medicine Pilot Grant University of Newcastle

Funding body Faculty of Health and Medicine Pilot Grant University of Newcastle
Scheme UON Faculty of Health and Medicine Pilot Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

20165 grants / $222,243

Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Project Team

Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz

Scheme Vanguard Grant
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

Regulators of the novel anti-angiogenic isoform: VEGF-A165b in obesity$60,000

Funding body: Diabetes Australia

Funding body Diabetes Australia
Project Team

Associate Professor Doan Ngo (Lead), Associate Professor Aaron Sverdlov

Scheme Research Grant
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

Early detection of chemotherapy-induced cardiomyopathy$50,000

Funding body: Royal Australasian College of Physicians

Funding body Royal Australasian College of Physicians
Project Team

Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo

Scheme Research Establishment Award
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Metabolic heart disease: markers and mechanisms$22,727

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo
Scheme Research Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo G1701494
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Are mitochondrial reactive oxygen species key mediators of metabolic syndrome-induced heart disease$14,516

Funding body: The University of Adelaide

Funding body The University of Adelaide
Scheme Shared
Role Lead
Funding Start 2016
Funding Finish 2016
GNo
Type Of Funding Internal
Category INTE
UON N

20152 grants / $470,000

Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$450,000

Awarded but not accepted

Funding body: The University of Sydney

Funding body The University of Sydney
Scheme -
Role Lead
Funding Start 2015
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

Start up grant$20,000

Funding body: University of Adelaide

Funding body University of Adelaide
Scheme Unknown
Role Lead
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Internal
Category INTE
UON N

20141 grants / $130,000

Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$130,000

Funding body: American Heart Association

Funding body American Heart Association
Scheme Postdoctoral Fellowship
Role Lead
Funding Start 2014
Funding Finish 2015
GNo
Type Of Funding International - Competitive
Category 3IFA
UON N

20131 grants / $3,100

Keystone Symposium Travel Grant$3,100

Funding body: The University of Adelaide

Funding body The University of Adelaide
Scheme Travel Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo
Type Of Funding Internal
Category INTE
UON N

20123 grants / $456,107

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$435,257

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team

A/Prof Aaron Sverdlov

Scheme Early Career Fellowships
Role Lead
Funding Start 2012
Funding Finish 2017
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$20,000

Funding body: Royal Australasian College of Physicians

Funding body Royal Australasian College of Physicians
Scheme Margorie Hooper Fellowship
Role Lead
Funding Start 2012
Funding Finish 2013
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Travel Award$850

Funding body: Seahorse Bioscience

Funding body Seahorse Bioscience
Scheme Travel Award
Role Lead
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding International - Non Competitive
Category 3IFB
UON N

20092 grants / $4,500

AHA 2009 Traveling Fellowship$3,000

Funding body: Cardiac Society of Australia and NewZealand

Funding body Cardiac Society of Australia and NewZealand
Scheme Travelling Fellowship
Role Lead
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Small Grant$1,500

Funding body: Heart Foundation

Funding body Heart Foundation
Scheme E O Myers Trust Fund Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

20082 grants / $61,600

Pathogenesis of aortic valve sclerosis$55,000

Funding body: CVL - Pfiser

Funding body CVL - Pfiser
Scheme Unknown
Role Lead
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Equipment grant$6,600

Funding body: Heart Foundation

Funding body Heart Foundation
Scheme J Fund Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

20051 grants / $85,000

Pathogenesis of aortic valve stenosis$85,000

Funding body: The University of Adelaide

Funding body The University of Adelaide
Scheme Faculty of Health Sciences Divisional PhD Scholarship
Role Lead
Funding Start 2005
Funding Finish 2010
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Supervision

Number of supervisions

Completed0
Current5

Total current UON EFTSL

PhD0.6

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2017 PhD Establishment and Evaluation of a nurse-led cardio-oncology Unit Nursing, Flinders University Co-Supervisor
2017 Post-Doctoral Fellowship Heart Failure pathophysiology and novel biomarkers Medical Science, University of Adelaide Co-Supervisor
2017 PhD Mechanisms of Obesity-Mediated Cardiac Dysfunction PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 Honours Heart failure: novel biomarkers Medical Science, University of Adelaide Co-Supervisor
2016 PhD The Use of N-acetylcysteine and Ramipril to improve clinical outcomes in Tako Tsubo Cardiomyopathy Medical Science, University of Adelaide Co-Supervisor
Edit

Research Opportunities

Early Detection of Chemotherapy-induced Cardiotoxicity

PhD

PHD

Faculty of Health and Medicine

1/01/2018 - 31/12/2020

Contact

Associate Professor Aaron Sverdlov
University of Newcastle
School of Medicine and Public Health
aaron.sverdlov@newcastle.edu.au

Edit

News

Heart Funding - small

Newcastle researchers awarded $750,000 to help heart health

December 11, 2017

Six Hunter researchers will focus on helping Australians have better heart health by investigating the causes, treatment and prevention of heart disease, after securing more than $750,000 in funding from the Heart Foundation.

Associate Professor Aaron Sverdlov

Position

Director of Heart Failure
Cardio-Metabolic and Heart Failure Groups
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email aaron.sverdlov@newcastle.edu.au
Phone (02) 4042 0725
Edit